Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results

被引：0

作者：

Gettinger, Scott N. ^{[1
]}

Bazhenova, Lyudmila ^{[2
]}

Salgia, Ravi ^{[3
]}

Langer, Corey J. ^{[4
]}

Gold, Kathryn A. ^{[5
]}

Rosell, Rafael ^{[6
,7
]}

Shaw, Alice ^{[8
]}

Weiss, Glen J. ^{[9
]}

Dorer, David J. ^{[10
]}

Rivera, Victor M. ^{[10
]}

Conlan, Maureen G. ^{[10
]}

Kerstein, David ^{[10
]}

Camidge, Ross ^{[11
]}

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[3] Univ Chicago Med, Chicago, IL USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Dexeus Univ Inst, Barcelona, Spain

[7] Catalan Inst Oncol, Barcelona, Spain

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Canc Treatment Ctr Amer, Goodyear, AZ USA

[10] Ariad Pharmaceut Inc, Cambridge, MA USA

[11] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

NSCLC; TKI; brigatinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL33.06

引用

页码：S238 / S239

页数：2

共 50 条

[1] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
Ahn, M.
Camidge, D. R.
Tiseo, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1755 - S1756
[2] Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK plus NSCLC
Camidge, D. R.
Ahn, M.
Reckamp, K.
West, H.
Huber, R.
Langer, C.
Bazhenova, L.
Leighl, N.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1893 - S1893
[3] Brigatinib in the first-line treatment of ALK plus metastatic NSCLC: safety and efficacy
Bronte, Giuseppe
Cafaro, Alessandro
Pasini, Luigi
Priano, Ilaria
Andrikou, Kalliopi
Cravero, Paola
Burgio, Marco Angelo
Delmonte, Angelo
Crino, Lucio
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (08) : 809 - 817
[4] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
Camidge, D. Ross
Tiseo, Marcello
Ahn, Myung-Ju
Reckamp, Karen
Hansen, Karin
Kim, Sang-We
Huber, Rudolf
West, Howard
Groen, Harry
Hochmair, Maximilian
Leighl, Natasha
Gettinger, Scott
Langer, Corey
Paz-Ares, Luis
Smit, Egbert
Kim, Edward
Reichmann, William
Clackson, Tim
Kerstein, David
Haluska, Frank
Kim, Dong-Wan
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1169
[5] Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALKþ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Gettinger, Scott N.
Huber, Rudolf M.
Kim, Dong-Wan
Bazhenova, Lyudmila
Hansen, Karin Holmskov
Tiseo, Marcello
Langer, Corey J.
Rodriguez, Luis G. Paz-Ares
West, Howard L.
Reckamp, Karen L.
Weiss, Glen J.
Smit, Egbert F.
Hochmair, Maximilian J.
Kim, Sang-We
Ahn, Myung-Ju
Kim, Edward S.
Groen, Harry J. M.
Pye, Joanna
Liu, Yuyin
Zhang, Pingkuan
Vranceanu, Florin
Camidge, Ross
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09):
[6] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Camidge, R.
Kim, H. R.
Ahn, M.
Yang, J. C.
Han, J.
Lee, J.
Hochmair, M.
Li, J. Y.
Chang, G.
Lee, K.
Gridelli, C.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D.
Bearz, A.
Griesinger, F.
Morabito, A.
Felip, E.
Califano, R.
Ghosh, S.
Spira, A.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
[7] UPDATED RESULTS OF A FIRST-IN-HUMAN DOSE-FINDING STUDY OF THE ALK/EGFR INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES
Camidge, D. Ross
Bazhenova, Lyudmila
Salgia, Ravi
Weiss, Glen J.
Langer, Corey J.
Shaw, Alice T.
Narasimhan, Narayana I.
Dorer, David J.
Rivera, Victor M.
Zhang, Joshua
Clackson, Tim
Haluska, Frank G.
Gettinger, Scott N.
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S296 - S297
[8] Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK plus NSCLC in the ALTA Trial
Camidge, D. R.
Tiseo, M.
Ahn, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1892
[9] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James C. H.
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki Hyeong
Delmonte, Angelo
Campelo, Maria Rosario Garcia
Kim, Dong-Wan
Griesinger, Frank
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander I.
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Liu, Yuyin
Vranceanu, Florin
Niu, Huifeng
Zhang, Pingkuan
Popat, Sanjay
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2091 - 2108
[10] Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC
Shaw, Alice
West, Howard
Socinski, Mark A.
Ou, Ignatius
Gandhi, Leena
Gadgeel, Shirish
Belani, Chandra P.
Shirai, Keisuke
Bazhenova, Lyudmila
Santos, Edgardo
Riely, Gregory J.
Chiappori, Alberto
Cetnar, Jeremy
Mekhail, Tarek
Chao, Bo
Borghaei, Hossein
Gold, Kathryn A.
Johannsdottir, Hrefna
Ruf, Thorsten
Boisserie, Frederic
Henschel, Volkmar
Zeaiter, Ali
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S237 - S238

← 1 2 3 4 5 →